Alvotech and Finesse Solutions, Inc. have entered into a collaboration under which Alvotech will employ Finesse’s SmartFactory cGMP single-use biomanufacturing platform suite, designed for scalable, flexible and cost-efficient manufacturing and lab technology. SmartFactory will add capacity to allow Alvotech to expand its biosimilars business. Additionally, Finesse customers will have access to Alvogen’s commercial, FDA-approved, biomanufacturing facility.
Dr. Andreas Herrmann, chief executive officer of Alvotech, said, “This partnership allows us to leverage Finesse’s single-use bio-manufacturing automation platform, combining best-of-breed bio-process equipment from upstream through downstream. This strategic relationship provides us with much-needed additional manufacturing capacity and scale-up capabilities which will allow us to expedite our ambitions to become a global leader in the high-growth biopharmaceutical industry. The first manufacturing suite will be in place by the end of 2015.”
Dr. Barbara Paldus, chief executive officer of Finesse, said, “Alvotech is capitalizing on the extraordinary flexibility afforded by SmartFactory, and together we will be able to implement cutting-edge, innovative solutions for established and development-stage biosimilars processes. The Alvotech facility will showcase our latest SMART technologies in process control, batch automation and data management. This partnership will also provide us with an important path to offer full-scale commercial manufacturing to our customers.”